Circadian Variations of Prostaglandin in Sleep Apnea
Primary Purpose
Sleep Apnea, Continuous Positive Airway Pressure, Prostaglandins
Status
Completed
Phase
Not Applicable
Locations
Japan
Study Type
Interventional
Intervention
CPAP treatment
Sponsored by

About this trial
This is an interventional treatment trial for Sleep Apnea focused on measuring Sleep apnea, CPAP, Prostaglandins, Circadian variations
Eligibility Criteria
Inclusion Criteria:
- Subjects on admission for sleep study under the Respiratory Care and Sleep Control Medicine, Kyoto University Hospital.
- Subjects diagnosed with OSA (apnea hypopnea index >=5/hour) by overnight polysomnography.
Exclusion Criteria:
- Subjects treating for acute infections or malignancy.
- Subjects with severe cardiovascular disease, diabetes,and renal failure.
- Subjects taking nonsteroidal anti-inflammatory drugs, steroids or immunosuppressants.
Sites / Locations
- Kyoto University Graduate School of Medicine
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
CPAP
Arm Description
The subjects introduced with CPAP treatment
Outcomes
Primary Outcome Measures
Prostaglandins in the urine and blood
Secondary Outcome Measures
polysomnography measurements
sleepiness and health-related quality of life
Clinical measurements (blood pressure, heart rate, sympathetic activity etc)
serum and urinary biomarker (inflammation, oxidative stress etc.)
endothelial function
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01096433
Brief Title
Circadian Variations of Prostaglandin in Sleep Apnea
Official Title
Association of Circadian Variations,Sleep Architecture, Hypertension, and Prostaglandin in Sleep Apnea
Study Type
Interventional
2. Study Status
Record Verification Date
January 2012
Overall Recruitment Status
Completed
Study Start Date
May 2010 (undefined)
Primary Completion Date
October 2011 (Actual)
Study Completion Date
January 2012 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Kyoto University
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this study is to evaluate the associations of circadian variations, sleep architecture, hypertension and prostanoids in the patients with sleep apnea. In addition, the patients introduced to continuous positive airway pressure(CPAP) treatment, the effects of CPAP are also evaluated.
Detailed Description
Obstructive sleep apnea (OSA) is characterized by repetitive episodes of upper airway obstruction during sleep that provoke frequents arousals, sleep fragmentation, oxygen desaturation, and excessive daytime sleepiness. OSA may contribute to the development of systemic hypertension, cardiovascular disease. Many studies has reported a crucial role for the prostaglandin D system in sleep regulation. In addition, it has been described urinary or blood levels of prostaglandins was higher in the patients with hypertension, diabetes mellitus, and these values were associated with the severity of coronary artery disease. However, the relation between alterations of prostaglandin D system and sleep architecture, sleepiness, and clinical outcomes such as hypertension, arteriosclerosis in the patients with OSA are not known. Additionally, after CPAP treatment, we will investigate the association between change of prostaglandin system and sleep architecture, sleepiness, clinical outcomes.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sleep Apnea, Continuous Positive Airway Pressure, Prostaglandins, Circadian Variations
Keywords
Sleep apnea, CPAP, Prostaglandins, Circadian variations
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
64 (Actual)
8. Arms, Groups, and Interventions
Arm Title
CPAP
Arm Type
Experimental
Arm Description
The subjects introduced with CPAP treatment
Intervention Type
Device
Intervention Name(s)
CPAP treatment
Other Intervention Name(s)
REMstar (Respironics), Auto Set(Resmed), Goodnight (Tyco Healthcare)
Intervention Description
maintains upper airway patency and minimizes the obstructive events
Primary Outcome Measure Information:
Title
Prostaglandins in the urine and blood
Time Frame
baseline, and 2days, 3 months after CPAP
Secondary Outcome Measure Information:
Title
polysomnography measurements
Time Frame
baseline, and 2days, 3 months after CPAP
Title
sleepiness and health-related quality of life
Time Frame
baseline, and 2days, 3 months after CPAP
Title
Clinical measurements (blood pressure, heart rate, sympathetic activity etc)
Time Frame
baseline, and 2days, 3 months after CPAP
Title
serum and urinary biomarker (inflammation, oxidative stress etc.)
Time Frame
baseline, and 2days, 3 months after CPAP
Title
endothelial function
Time Frame
baseline, and 2days, 3 months after CPAP
10. Eligibility
Sex
All
Minimum Age & Unit of Time
20 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Subjects on admission for sleep study under the Respiratory Care and Sleep Control Medicine, Kyoto University Hospital.
Subjects diagnosed with OSA (apnea hypopnea index >=5/hour) by overnight polysomnography.
Exclusion Criteria:
Subjects treating for acute infections or malignancy.
Subjects with severe cardiovascular disease, diabetes,and renal failure.
Subjects taking nonsteroidal anti-inflammatory drugs, steroids or immunosuppressants.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kazuo Chin, MD,PhD
Organizational Affiliation
Kyoto University, Graduate School of Medicine
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Yuichi Chihara, MD
Organizational Affiliation
Kyoto University Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Kyoto University Graduate School of Medicine
City
Kyoto
Country
Japan
12. IPD Sharing Statement
Citations:
PubMed Identifier
23222881
Citation
Chihara Y, Chin K, Aritake K, Harada Y, Toyama Y, Murase K, Yoshimura C, Hitomi T, Oga T, Mishima M, Urade Y. A urine biomarker for severe obstructive sleep apnoea patients: lipocalin-type prostaglandin D synthase. Eur Respir J. 2013 Dec;42(6):1563-74. doi: 10.1183/09031936.00133512. Epub 2012 Dec 6.
Results Reference
derived
Learn more about this trial
Circadian Variations of Prostaglandin in Sleep Apnea
We'll reach out to this number within 24 hrs